To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure
Study Type
OBSERVATIONAL
Enrollment
13,248
Changes in morning blood pressure (BP)
Time frame: Pre-dose, up to 6 months after start of treatment
Changes in metabolic laboratory parameters
Time frame: Pre-dose, up to 6 months after start of treatment
Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP
Time frame: Pre-dose, up to 6 months after start of treatment
Investigator assessment of efficacy in reducing morning hypertension on a 5-point rating scale
Time frame: Up to 6 months after start of treatment
Investigator assessment of effects on metabolism on a 3-point rating scale
Time frame: Up to 6 months after start of treatment
Investigator assessment of tolerability on a 5-point rating scale
Time frame: Up to 6 months after start of treatment
Number of patients with adverse events
Time frame: Up to 6 months
Changes in morning heart rate
Time frame: Pre-dose, up to 6 months after start of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.